Securities code: 300636 securities abbreviation: Jiangxi Synergy Pharmaceutical Co.Ltd(300636) Announcement No.: 2022-003 bond Code: 123073 bond abbreviation: Tonghe convertible bond
Jiangxi Synergy Pharmaceutical Co.Ltd(300636)
Announcement of resolutions of the fourth meeting of the third board of supervisors
The company and all members of the board of supervisors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Meetings of the board of supervisors
The fourth meeting of the third board of supervisors (hereinafter referred to as the “meeting”) of Jiangxi Synergy Pharmaceutical Co.Ltd(300636) (hereinafter referred to as the “company”) sent a meeting notice to all supervisors by telephone and e-mail on January 6, 2022. It was held in the company’s conference room by on-site voting on January 11, 2022. Three supervisors should attend the meeting and three actually attended the meeting. The meeting was presided over by Mr. Yu shaojiong, chairman of the board of supervisors. The convening, convening and voting procedures of the meeting were in accordance with the company law of the people’s Republic of China and other relevant laws and regulations and the articles of association, and the meeting was legal and effective.
2、 Deliberation at the meeting of the board of supervisors
After careful deliberation by the supervisors attending the meeting, the following resolutions were adopted by open ballot:
1. The proposal on adjusting the implementation progress of the company’s investment projects with raised funds was deliberated and adopted
The board of supervisors believes that the company’s adjustment of the implementation progress of the raised funds investment project is a prudent decision made according to the actual progress of the project, which only involves the change of the project implementation progress, the implementation subject and investment direction of the raised funds investment project remain unchanged, and there is no change or disguised change of the investment direction of the raised funds and other situations that damage the interests of shareholders, It will not have a significant adverse impact on the normal operation of the company, and comply with the relevant provisions of China Securities Regulatory Commission and Shenzhen Stock Exchange on the management of raised funds of listed companies. The board of supervisors agreed to the company’s adjustment of the implementation progress of the investment project with raised funds.
Voting results: 3 in favor, 0 against and 0 abstention.
2. The proposal on the implementation of new, modified and expanded projects of some workshops and devices in the second plant area of the company was reviewed and approved
It is agreed that the company will implement the new, reconstruction and expansion projects of some workshops and devices in plant area 2 based on the phase I project of plant area 2, mainly including the construction and reconstruction of some solvent tank farms, utilities and the expansion and reconstruction of some workshops. The project is planned to start construction in 2022, with a total construction period of 4 years and a total investment of 1415.6075 million yuan, including 1223.8887 million yuan of construction investment, 146 million yuan of initial working capital and 45.7188 million yuan of interest during the construction period.
Voting results: 3 in favor, 0 against and 0 abstention.
This proposal needs to be submitted to the first extraordinary general meeting of shareholders of the company in 2022 for deliberation.
3、 Documents for future reference
1. Resolution of the 4th meeting of the 3rd board of supervisors of the company.
It is hereby announced.
Jiangxi Synergy Pharmaceutical Co.Ltd(300636) board of supervisors January 11, 2002
